ストックスクリーナーアプリを入手
1.03
5.50%
-0.06
前日終値:
$1.09
開ける：
$1.09
24時間の取引高:
43,254
Relative Volume:
0.44
時価総額：
$16.39M
収益：
$345.00K
当期純損益:
$-11.25M
株価収益率:
-1.4272
EPS:
-0.7217
ネットキャッシュフロー:
$-16.70M
1週間 パフォーマンス:
-14.88%
1か月 パフォーマンス:
-22.56%
6か月 パフォーマンス:
-8.04%
1年 パフォーマンス:
-33.12%
1日の値動き範囲:
$1.03
$1.10
1週間の範囲:
$1.01
$1.23
52週間の値動き範囲:
$0.7687
$1.8395
Allarity Therapeutics Inc Stock (ALLR) Company Profile
名前
Allarity Therapeutics Inc
セクター
電話
401-426-4664
住所
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.03 | 16.39M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc (ALLR) 最新ニュース
ALLR - Finviz
Form 8K Allarity Therapeutics Inc For: 17 September By Investing.com - Investing.com India
Allarity Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Ascendiant Capital maintains Buy rating on Allarity Therapeutics, $11 price target - TradingView
A cancer test to find patients likely to benefit gets a Japan patent - Stock Titan
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development - Investing News Network
Form 8K Allarity Therapeutics Inc For: 14 September By Investing.com - Investing.com India
Allarity Therapeutics-backed SPAC files S-1 for $100M IPO; sponsor to hold ~25% - tradingview.com
Allarity Therapeutics files for $100 million SPAC offering By Investing.com - Investing.com Australia
Allarity Therapeutics Inc (ALLR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement - Investing News Network
Allarity Therapeutics files for $100 million SPAC offering - Investing.com
Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement - TradingView
A former Novo Nordisk president will chair Allarity’s new acquisition company. The proposed offering is $100 million. - Stock Titan
Allarity Therapeutics Stock Price Forecast. Should You Buy ALLR? - StockInvest.us
Allarity Therapeutics Inc (ALLR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Allarity Therapeutics Inc (ALLR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Allarity Therapeutics Inc (ALLR) Peer Comparison – Compare with Others - Value Research
Allarity (ALLR) Financial Update: EPS Clears the Reported Estimate in the Latest Session; Trading Response: The Stock Closes Near Unchanged at the CloseEBITDA Estimate Trend - vinanet.vn
Allarity (ALLR) Earnings Update: The Available Earnings Metric Delivers a Beat; Price Move: Shares Move 5.93% Higher for the Current SessionEarnings Seasonality - vinanet.vn
Allarity Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Investing News Network
Allarity Therapeutics Q2 EPS of $(0.21) beats $(0.25) estimate - scanx.trade
Allarity Therapeutics reports Q2 results, cash position - Investing.com
Allarity Therapeutics, Inc. 2026: Revenue $0 Net income ($3.41M), EPS ($0.21) — 10-Q Summary - TradingView
Allarity Therapeutics reports Q2 results, cash position By Investing.com - Investing.com Canada
Allarity Therapeutics (ALLR) adds $20M debt, holds $26.9M cash in Q2 2026 - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready ... - Caledonian Record
Patent Gives Allarity’s Cancer-Drug Pairing Exclusivity Into 2042 - Stock Titan
Allarity Therapeutics Reports Second Quarter 2026 Results - GlobeNewswire
Allarity Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss of -$0.17 Highlights Cost DisciplineRevenue Warning Signal - dars.gov.et
Allarity Therapeutics (ALLR) Edges Higher: Biotech Stock Tests Key $1.42 Resistance After +1.5% MoveWyckoff Upthrust - careplusvn.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Allarity Therapeutics (ALLR) Gains 2.48% as Stock Holds Above Key Support ZoneDividend ETF - dars.gov.et
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics (ALLR) Slips 1.65% as Stock Tests Key Support LevelsHidden Order - careplusvn.com
Allarity Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLR - TradingView
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190| - TradingKey
TradingKey - TradingKey
Allarity Therapeutics Inc (ALLR) Income Statement - TradingKey
ALLR Q1 2026 Earnings: EPS Beat by 24.24% as Pre-Revenue Biotech Faces Market SkepticismEarnings Risk Report - dars.gov.et
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - Yahoo Finance UK
Allarity Therapeutics Inc (ALLR) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):